COMBINATION SECOND-LINE THERAPY FOR RHEUMATOID ARTHRITIS
نویسندگان
چکیده
منابع مشابه
Combination second-line therapy for rheumatoid arthritis.
WHILE the treatment of RA has become more aggressive in recent years by the earlier use of second-line agents, remissions, as measured by the ACR [1], resulting from these therapies are rare. Concern has been expressed that the mortality risk in patients with RA is similar to that seen in Stage IV Hodgkin's disease or three vessel coronary artery disease [2]. Certainly, the consideration of dis...
متن کاملOutcome of second line therapy in rheumatoid arthritis.
OBJECTIVES To study the functional outcome in patients with rheumatoid arthritis (RA) who tolerate second line drug therapy for five years. METHODS We enrolled into prospective controlled trials, 190 patients with rheumatoid arthritis who tolerated 'disease modifying' antirheumatic drug therapy for five years. Demographic data were recorded. Disease activity was measured every six months for ...
متن کاملCombination therapy in rheumatoid arthritis.
It has become clear that early suppression of rheumatoid arthritis disease activity is important in preventing progressive joint destruction and functional decline. To achieve this goal, many rheumatologists today advocate a more aggressive approach, using combinations of classic disease-modifying antirheumatic drugs-often including methotrexate-or new drugs. During the last 2 years, the combin...
متن کاملCombination DMARD therapy for rheumatoid arthritis.
approaches needs to be considered; triple therapy has been reported to be well tolerated at three to five years, while similar data are not available for methotrexate and cyclosporin A. The success of combination DMARD therapy in recent double blind controlled studies is encouraging.2223 As is frequently the case, however, the success of these approaches raises as many questions as it answers. ...
متن کاملCombination therapy with cyclosporin in rheumatoid arthritis.
The role of combination therapy in rheumatoid arthritis (RA) is increasing with the development of new treatment modalities. Past combinations of slow-acting anti-rheumatic drugs resulted in either excessive side-effects or lack of efficacy over single-agent therapy. However, refined methodology and a better understanding of the mechanism of action of newer agents have led to improved combinati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 1994
ISSN: 1462-0324,1462-0332
DOI: 10.1093/rheumatology/33.7.603